Advanced search
Publication Cover
Platelets Volume 34, 2023 - Issue 1
Submit an article Journal homepage
3,170
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases

Xiaofei Song1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Jiaqian Qi1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Xueqian Li1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Meng Zhou1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Jingyi He1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Tiantian Chu1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
&
Yue Han1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China;4 State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7560-7195View further author information
ORCID Icon show all
Article: 2229905 | Received 11 Nov 2022, Accepted 21 Jun 2023, Published online: 06 Jul 2023

References

  • Liu Y, Zhang Y, Chen D, Fu Y. Current status of and global trends in platelet transfusion refractoriness from 2004 to 2021: a bibliometric analysis. Front Med. 2022;9:873500. doi:10.3389/fmed.2022.873500. Epub 2022/05/24.
  • Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122(1):10–8. doi:10.1046/j.1365-2141.2003.04468.x. Epub 2003/06/26.
  • Rebulla P. Formulae for the definition of refractoriness to platelet transfusion. Transfus Med. 1993;3:91–3. doi:10.1111/j.1365-3148.1993.tb00108.x. Epub 1993/03/01.
  • Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297–305. doi:10.1111/bjh.13597. Epub 2015/07/22.
  • Forest SK, Hod EA. Management of the platelet refractory patient. Hematol Oncol Clin North Am. 2016;30(3):665–77. doi:10.1016/j.hoc.2016.01.008. Epub 2016/04/27.
  • Saris A, Pavenski K. Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfus Med Rev. 2020;34(4):250–7. doi:10.1016/j.tmrv.2020.09.010. Epub 2020/11/01.
  • Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106–14. doi:10.1182/blood-2003-08-2724. Epub 2005/02/05.
  • Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–60. doi:10.1111/j.1365-2141.2008.07189.x. Epub 2008/05/31.
  • Belizaire R, Makar RS. Non-alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion. Transfus Med Rev. 2020;34(4):242–9. doi:10.1016/j.tmrv.2020.09.002. Epub 2020/11/02.
  • Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, Bérard E, Delabesse E, Luquet I, Martinez S, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62–7. doi:10.1016/j.leukres.2017.08.015. Epub 2017/09/15.
  • Arabi S, Almahayni AO, Alomair AA, Masuadi EM, Damlaj M, Al-Dorzi HM. Prevalence, risk factors, and outcomes of platelet transfusion refractoriness in critically ill patients: a retrospective cohort study. Crit Care Res Pract. 2021;2021:1–11. doi:10.1155/2021/5589768. Epub 2021/10/05.
  • Blandin L, Dougé A, Fayard A, Bay JO, Berlie G, Pereira B, Lemal R, Rouzaire P. Platelet transfusion refractoriness and anti-HLA immunization. Transfusion. 2021;61(6):1700–4. doi:10.1111/trf.16358. Epub 2021/03/13.
  • Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ, Stubbs JR, Kreuter JD. How do I … manage the platelet transfusion-refractory patient? Transfusion. 2017;57:2828–35. doi:10.1111/trf.14316. Epub 2017/09/30.
  • Hayashi T, Hirayama F. Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping. Blood Transfus. 2015;13:380–90. doi:10.2450/2015.0275-14. Epub 2015/06/10.
  • Zhao C, Zhao XS, Wang Y, Yan CH, Xu LP, Zhang XH, Liu KY, Huang XJ, Sun YQ. Incidence and clinical significance of platelet transfusion refractoriness after allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2022;43:738–44. Epub 2023/01/29.
  • Tanoue S, Konuma T, Kato S, Oiwa-Monna M, Isobe M, Jimbo K, Takahashi S, Tojo A. Platelet transfusion refractoriness in single-unit cord blood transplantation for adults: risk factors and clinical outcomes. Biol Blood Marrow Transplant. 2018;24(9):1873–80. doi:10.1016/j.bbmt.2018.05.006. Epub 2018/05/14.
  • Pozo AL, Godfrey EM, Bowles KM. Splenomegaly: investigation, diagnosis and management. Blood Rev. 2009;23(3):105–11. doi:10.1016/j.blre.2008.10.001. Epub 2008/12/09.
  • Aldulaimi S, Mendez AM. Splenomegaly: diagnosis and management in adults. Am Fam Physician. 2021;104:271–6. Epub 2021/09/16.
  • Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–80. doi:10.1056/NEJMoa1212772. Epub 2013/05/10.
  • Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest. 1966;45(5):645–57. doi:10.1172/JCI105380. Epub 1966/05/01.
  • Li Y, Ryan J, Xu F, Vostal JG. Macrophage depletion mitigates platelet aggregate formation in splenic marginal zone and alleviates LPS-Associated Thrombocytopenia in Rats. Front Med. 2019;6:300. doi:10.3389/fmed.2019.00300. Epub 2020/01/11.
  • Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D’Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kröger NM, Mesa R, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the chronic malignancies working party of the EBMT. Lancet Haematol. 2023;10:e59–e70. doi:10.1016/S2352-3026(22)00330-1. Epub 2022/12/10.
  • Mauro M, Camoglio F, Piccoli P, De Bortoli M, Balter R, Pegoraro A, Cesaro S. The use of splenectomy to manage platelet transfusion refractoriness due to anti-human leukocyte antibodies in allogeneic stem cell transplantation. Pediatr Rep. 2016;8(1):6159. doi:10.4081/pr.2016.6159. Epub 2016/04/27.
  • Machado NO, Grant CS, Alkindi S, Daar S, Al-Kindy N, Al Lamki Z, Ganguly SS. Splenectomy for haematological disorders: a single center study in 150 patients from Oman. Int J Surg. 2009;7(5):476–81. doi:10.1016/j.ijsu.2009.08.004. Epub 2009/08/22.
  • Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Splenic irradiation for splenomegaly: a systematic review. Cancer Treat Rev. 2017;53:47–52. doi:10.1016/j.ctrv.2016.11.016. Epub 2017/01/08.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.